DEF 14A: Bone Biologics Corporation Announces Annual Meeting of Stockholders

Bone Biologics Corporation will hold its 2024 Annual Meeting of Stockholders on September 17, 2024, to elect directors, approve executive compensation, and ratify the appointment of its independent accounting firm.

Summary

• Bone Biologics Corporation is holding its Annual Meeting of Stockholders on September 17, 2024, at its Burlington, MA offices.
• Stockholders can also listen to the meeting via telephone.
• The meeting will address the election of four directors, an advisory vote on executive compensation, and the ratification of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The record date for determining stockholders eligible to vote is July 19, 2024.
• Proxy materials were made available to stockholders on or about August 8, 2024.
• Stockholders can vote via the internet, telephone, mail, or in person at the Annual Meeting.

Sentiment

Score: 4

Explanation: The document is primarily informational, but the financial results and stock performance suggest a cautious outlook. The company is pre-revenue and faces significant challenges in developing and commercializing its technology.

Positives

• The company is providing multiple avenues for stockholders to vote, including internet, telephone, mail, and in person.
• The Board recommends voting FOR all proposals.
• The company is utilizing e-proxy rules to reduce environmental impact and costs.

Negatives

• The company incurred a net loss of $(8,948,731) in 2023 and $(1,484,620) in 2022.
• The value of an initial $100 investment on October 13, 2021, was only $0.37 on December 29, 2023, indicating a significant decrease in shareholder value.

Risks

• The company is subject to risks associated with achieving clinical development objectives, business development goals, capital raising, and investor goals.
• The company is a pre-revenue medical device development stage entity, which carries inherent risks.
• The company's success depends on motivating executives to meet strategic operational and financial goals.

Future Outlook

The document does not contain specific forward-looking financial guidance, but it outlines the company's ongoing efforts to develop its technology and achieve its strategic goals.

Management Comments

• Don Hankey, Chairman of the Board, encourages stockholders to vote.
• The Board believes it is important to select the Company's Chairman and Chief Executive Officer in the manner it considers in the best interests of the Company at any given time.

Industry Context

Bone Biologics operates in the orthobiologics and medical device industry, focusing on bone regeneration for spinal fusion. The company's activities are subject to regulatory oversight and competition from other companies in the medical device space.

Comparison to Industry Standards

• It is difficult to compare Bone Biologics directly to industry standards due to its pre-revenue status and focus on a specific technology.
• Companies like Medtronic, Stryker, and Zimmer Biomet are established players in the broader orthopedics market, but they have diversified product portfolios and significant revenue streams.
• Bone Biologics' financial performance and market capitalization are significantly smaller than these industry giants.
• The company's success depends on its ability to successfully develop and commercialize its technology, which is a common challenge for early-stage medical device companies.

Legal Proceedings

• A settlement agreement was reached in January 2024 regarding a complaint filed in 2019, with the company paying $750,000 to the plaintiffs.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will impact the company's governance and executive compensation.
• Executive compensation is designed to align with the company's strategic goals and performance.
• The outcome of the Annual Meeting will influence the company's direction and future performance.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on September 17, 2024.
• The Board and committees will consider the outcome of the votes when making future decisions.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Weinberg & Company, Directors, Voting, Bone Biologics, BBLG